Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.37 |
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.37 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.36 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | TSG101 | Q99816 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4824283 | 0.91 | PDF (0.43) | TACR1FKBP4HDAC3HDAC1HDAC2 | |
| SCHEMBL3513112 | 0.88 | FKBP4 (0.44) | TACR1FKBP4NMUR2ITGB1ITGA4 | |
| SCHEMBL1088249 | 0.87 | TACR1 (0.41) | TACR1FKBP4ITGB1ITGA4HDAC3 | |
| SCHEMBL1078320 | 0.87 | TACR1 (0.42) | TACR1FKBP4 | |
| SCHEMBL8502170 | 0.86 | OPRM1 (0.42) | TACR1FKBP4OPRM1OPRK1EPHA2 | |
| SCHEMBL3314831 | 0.85 | TACR1 (0.41) | TACR1FKBP4 | |
| SCHEMBL3242151 | 0.85 | OPRM1 (0.40) | TACR1FKBP4OPRM1OPRK1EPHA2 | |
| SCHEMBL3926322 | 0.85 | TACR1 (0.41) | TACR1FKBP4 | |
| SCHEMBL366333 | 0.85 | TACR1 (0.51) | TACR1FKBP4ITGB1ITGA4 | |
| SCHEMBL4898024 | 0.84 | TACR1 (0.42) | TACR1FKBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102245635-B | Modified variant BOWMAN BIRK protease inhibitors | 丹尼斯科美国公司 | 2016-08-31 | — | — | CN | disclosed |
| US-9084734-B2 | Peptide personal care compositions and methods for their use | DANISCO US INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8962796-B2 | Modified variant Bowman Birk protease inhibitors | DANISCO US INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2344531-B1 | MODIFIED VARIANT BOWMAN BIRK PROTEASE INHIBITORS | DANISCO US INC (US) | 2014-12-10 | — | — | EP | disclosed |
| US-20130195781-A1 | Modified Variant Bowman Birk Protease Inhibitors | DANISCO US INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8394941-B2 | Modified variant Bowman Birk Protease Inhibitors | DANISCO US INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120014885-A1 | Personal Care Compositions and Methods for Their Use | DANISCO US INC. | 2012-01-19 | — | — | US | disclosed |
| US-20110256608-A1 | Modified Variant Bowman Birk Protease Inhibitors | DANISCO US INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-2344531-A1 | MODIFIED VARIANT BOWMAN BIRK PROTEASE INHIBITORS | Danisco US Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-1680507-B1 | BACTERIAL EXPRESSION OF PROTEASE INHIBITORS AND VARIANTS THEREOF | GENENCOR INT (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20020114734-A1 | Microplate thermal shift assay apparatus for ligand development and multi-variable protein chemistry optimization | Life Technologies Corporation | 2002-08-22 | — | — | US | disclosed |
| US-6303322-B1 | TESTING IN MULTIPLICITY OF WELLS; GENERATING THERMAL UNFOLDING OR DENATURATION CURVE; COMBINATORIAL CHEMISTRY; RECEPTOR BINDING ASSAY | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-10-16 | — | — | US | disclosed |
| US-6291192-B1 | GENE EXPRESSION OF HETEROLOGOUS PROTEIN IN INCLUSION BODY OF HOST; RECOVERING BY FOLDING OR RENATURING; RANKING EFFICACIES; GENERATING THERMAL DENATURATION CURVE | 3-DIMENSIONAL PHARMACEUTICALS INC. | 2001-09-18 | — | — | US | disclosed |
| US-6291191-B1 | MONITORING PARTICLES RESPONSE TO PREFERENTIAL POLYPEPTIDES; INCUBATE POLYPEPTIDES WITH SAMPLE, HEAT SAMPLE, MEASURE ADJUSTMENTS, DETECT MELTING POINT, COMPARE RESPONSE TO TARGET POLYPEPTIDES, MEASURE EQUILIBRIUM DISSOCIATION | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| US-6268158-B1 | GENERATING THERMAL DENATURATION CURVE | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-07-31 | — | — | US | disclosed |
| US-6268218-B1 | HEATING SAMPLES, SHINING EXCITATORY LIGHT TOWARDS SAMPLES, SENSING EMISSIONS, GENERATING THERMAL UNFOLDING DATA, GENERATING THERMAL UNFOLDING CURVES, THEN COMPARING CURVES; MULTIVARIABLE METHOD FOR OPTIMIZING SHELF LIFE OF TARGET | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-07-31 | — | — | US | disclosed |
| US-6232085-B1 | GENERATING THERMAL DENATURATION CURVE | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-05-15 | — | — | US | disclosed |
| US-6214293-B1 | ASSAY APPARATUS THAT INCLUDES A TEMPERATURE ADJUSTING MEANS FOR SIMULTANEOUSLY HEATING A PLURALITY OF SAMPLES AND A RECEIVING MEANS FOR RECEIVING SPECTRAL EMISSION FROM THE SAMPLES WHILE THE SAMPLES ARE BEING HEATED | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-04-10 | — | — | US | disclosed |
| US-6036920-A | FOR SENSING FLUORESCENT EMISSIONS FROM A PLURALITY OF HEATED SAMPLES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| US-6020141-A | Microplate thermal shift assay for ligand development and multi-variable protein chemistry optimization | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014885-A1 | Personal Care Compositions and Methods for Their Use | CUTA, VEGFA, BDNF | TACR1 1639/4885FKBP4 1505/4885NMUR2 4217/4885 |
| US-20130195781-A1 | Modified Variant Bowman Birk Protease Inhibitors | SERPINB1, BBC3, BRAP | TACR1 2881/4885FKBP4 1224/4885NMUR2 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.